Detection of MRD Using Heminested Fluorescent PCR or Dot Blot Assay
| Patient No. . | TCR Rearrangement . | Patient's Leukemia-Specific Probe† . | End of Induction Therapy, 6-7 Weeks . | 12-15 Weeks . | 35-40 Weeks . | MRD at End of Therapy . | Length of First CCR (mo) . | Status of Disease . |
|---|---|---|---|---|---|---|---|---|
| CT1 | Vδ1Jδ1 | ctATTGCGCTTAGTGg | +/+ | +/− | −/− | −/− | +57 | First CCR |
| CT2 | Vδ1Jδ1 | ggatacgCTCTACTTcaccg | +/+ | +/− | +/− | NP | 12 | Relapse BM |
| CT3 | Vδ3Jδ1 | tagGGCCTGGAGCTAcc | +/+ | +/− | −/− | −/− | +125 | First CCR |
| CT4 | Vδ1Jδ1 | gggCCCCATCGGTacac | +/+* | +/+ | +/+ | NP | 11 | Relapse BM |
| CT5 | Vδ3Jδ1 | gcctCTACCGTAGGtag | −/− | −/− | −/− | −/− | +33 | First CCR |
| CT6 | Vγ2-Jγ1.3 | gggCTAGATCCCTAgat | +/+ | +/+ | +/+ | NP | 20 | Relapse BM |
| CT7 | Vδ3Jδ3 | GGTTATGTTGTTGAAGTTCGT | +/+ | +/+ | +/+ | NP | 20 | Relapse BM |
| CT8 | Vγ6-Jγ1.3 | gataggTCCGTTACGTAg | +/+* | +/+* | +/+ | NP | 10 | Relapse BM |
| CT9 | Vδ1Jδ2 | gaactGCATTGGCCTCTAc | +/+ | +/+ | −/− | TE | +21 | First CCR |
| CT11 | Vδ3Jδ1 | AGCAGATCCCGACGGGTA | +/+ | +/− | +/− | NP | 18 | Relapse BM-CNS |
| CT12 | Vδ2Dδ3 | gacACCGGGAGAAATGact | +/+* | +/+ | +/+ | TE | +18 | First CCR |
| CT14 | Vδ1Jδ1 | ggAATTGccactggg | +/+* | +/+ | +/+ | NP | 12 | Relapse BM |
| CT15 | Dδ2Jδ1 | cttcttacTAGCCCAGCG | +/+* | +/+* | NP | NP | 8 | Relapse BM |
| CT16 | Dδ2Jδ1 | cttacGTACCGGATaca | +/+ | +/− | −/− | −/− | +38 | First CCR |
| CT18 | Vδ2Jδ1 | GGGGACTAACTATGCCCC | +/+ | +/− | −/− | −/− | +55 | First CCR |
| CT21 | Vδ2Jδ1 | ctacCCCGAAGCGCCGAG | +/+ | +/− | −/− | −/− | +33 | First CCR |
| CT22 | Vδ1Jδ1 | gggTTAGGTATTTATacac | +/+ | +/+ | −/− | −/− | +20 | First CCR |
| Patient No. . | TCR Rearrangement . | Patient's Leukemia-Specific Probe† . | End of Induction Therapy, 6-7 Weeks . | 12-15 Weeks . | 35-40 Weeks . | MRD at End of Therapy . | Length of First CCR (mo) . | Status of Disease . |
|---|---|---|---|---|---|---|---|---|
| CT1 | Vδ1Jδ1 | ctATTGCGCTTAGTGg | +/+ | +/− | −/− | −/− | +57 | First CCR |
| CT2 | Vδ1Jδ1 | ggatacgCTCTACTTcaccg | +/+ | +/− | +/− | NP | 12 | Relapse BM |
| CT3 | Vδ3Jδ1 | tagGGCCTGGAGCTAcc | +/+ | +/− | −/− | −/− | +125 | First CCR |
| CT4 | Vδ1Jδ1 | gggCCCCATCGGTacac | +/+* | +/+ | +/+ | NP | 11 | Relapse BM |
| CT5 | Vδ3Jδ1 | gcctCTACCGTAGGtag | −/− | −/− | −/− | −/− | +33 | First CCR |
| CT6 | Vγ2-Jγ1.3 | gggCTAGATCCCTAgat | +/+ | +/+ | +/+ | NP | 20 | Relapse BM |
| CT7 | Vδ3Jδ3 | GGTTATGTTGTTGAAGTTCGT | +/+ | +/+ | +/+ | NP | 20 | Relapse BM |
| CT8 | Vγ6-Jγ1.3 | gataggTCCGTTACGTAg | +/+* | +/+* | +/+ | NP | 10 | Relapse BM |
| CT9 | Vδ1Jδ2 | gaactGCATTGGCCTCTAc | +/+ | +/+ | −/− | TE | +21 | First CCR |
| CT11 | Vδ3Jδ1 | AGCAGATCCCGACGGGTA | +/+ | +/− | +/− | NP | 18 | Relapse BM-CNS |
| CT12 | Vδ2Dδ3 | gacACCGGGAGAAATGact | +/+* | +/+ | +/+ | TE | +18 | First CCR |
| CT14 | Vδ1Jδ1 | ggAATTGccactggg | +/+* | +/+ | +/+ | NP | 12 | Relapse BM |
| CT15 | Dδ2Jδ1 | cttcttacTAGCCCAGCG | +/+* | +/+* | NP | NP | 8 | Relapse BM |
| CT16 | Dδ2Jδ1 | cttacGTACCGGATaca | +/+ | +/− | −/− | −/− | +38 | First CCR |
| CT18 | Vδ2Jδ1 | GGGGACTAACTATGCCCC | +/+ | +/− | −/− | −/− | +55 | First CCR |
| CT21 | Vδ2Jδ1 | ctacCCCGAAGCGCCGAG | +/+ | +/− | −/− | −/− | +33 | First CCR |
| CT22 | Vδ1Jδ1 | gggTTAGGTATTTATacac | +/+ | +/+ | −/− | −/− | +20 | First CCR |
Results of heminested fluorescent PCR and dot blot assay are reported before and after the slash, respectively.
Abbreviations: NP, not performed (patients relapsed before this time point); BM, bone marrow; TE, too early.
Greater than 5% of lymphoblasts detectable by morphologic observation of BM aspirates.
Capital letter indicates the junction sequence of the rearranged segments.